EGFR haplotypes confer risk for tyrosine kinase domain mutations in non-small cell lung cancer

被引：0
|
作者：
Liu, Wanqing
He, Lijun
Krishnaswamy, Soundararajan
Kanteti, Rajani
Wang, Yi-Ching
Salgia, Ravi
Ratain, Mark
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Natl Cheng Kung Univ, Tainan 701, Taiwan
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3928
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS
    Nasu, Shingo
    Takata, So
    Masuhiro, Kentaro
    Morita, Satomu
    Iwata, Kaori
    Ryota, Noriko
    Okada, Yukari
    Tokuoka, Yoshie
    Ueda, Yuki
    Kumode, Akinori
    Usui, Naoko
    Tanaka, Ayako
    Shiroyama, Takayuki
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Hirashima, Tomonori
    [J]. RESPIROLOGY, 2017, 22 : 114 - 114
  • [32] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
    Yiming Zhao
    Shuyuan Wang
    Bo Zhang
    Rong Qiao
    Jianlin Xu
    Lele Zhang
    Yanwei Zhang
    Baohui Han
    [J]. Targeted Oncology, 2019, 14 : 169 - 178
  • [33] Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
    Nakazawa, S.
    Pecci, F.
    Ricciuti, B.
    Harada, G.
    Lee, J. K.
    Alessi, J. V.
    Barrichello, A. P. C.
    Vaz, V. R.
    Lamberti, G.
    Di Federico, A.
    Gandhi, M. M.
    Gazgalis, D.
    Feng, W. W.
    Jiang, J.
    Chen, M.
    Lee, E.
    Haradon, D.
    Smokovich, A.
    Voligny, E.
    Nguyen, T.
    Goel, V.
    Zimmerman, Z.
    Wang, X.
    Bahcall, M.
    Heist, R.
    Iqbal, S.
    Che, J.
    Schrock, A. B.
    Drilon, A.
    Janne, P. A.
    Awad, M. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S88 - S89
  • [34] Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
    Kanazu, Masaki
    Mori, Masahide
    Kimura, Madoka
    Nishino, Kazumi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Ihara, Shoichi
    Komuta, Kiyoshi
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kumagai, Toru
    Imamura, Fumio
    [J]. THORACIC CANCER, 2021, 12 (01) : 90 - 96
  • [35] Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations:A Retrospective Analysis
    刘华丽
    韩光
    彭敏
    翁一鸣
    袁静萍
    杨桂芳
    于金明
    宋启斌
    [J]. Journal of Huazhong University of Science and Technology(Medical Sciences), 2017, 37 (06) : 864 - 872
  • [36] Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Alfredo Tartarone
    Rosa Lerose
    Chiara Lazzari
    Vanesa Gregorc
    Michele Aieta
    [J]. Medical Oncology, 2014, 31
  • [37] Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
    Peng, Liang
    Song, Zhi-Gang
    Jiao, Shun-Chang
    [J]. SCIENTIFIC REPORTS, 2014, 4
  • [38] Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
    Liang Peng
    Zhi-Gang Song
    Shun-Chang Jiao
    [J]. Scientific Reports, 4
  • [39] Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Tartarone, Alfredo
    Lerose, Rosa
    Lazzari, Chiara
    Gregorc, Vanesa
    Aieta, Michele
    [J]. MEDICAL ONCOLOGY, 2014, 31 (08)
  • [40] Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer To Test or Not to Test?
    Gazdar, Adi F.
    [J]. MEDICINE, 2011, 90 (03) : 168 - 170
12345